Measuring the Incidence of Hospital Readmissions Based on Adverse Drug Events

February 25, 2014 updated by: prof. dr. Neree Claes, Hasselt University

Measuring the Incidence of Hospital Readmissions, Caused by Adverse Drug Events (ADE) Due to Anticoagulants in Vzw Jessa Hospital (Belgium)

An ADE is defined as harm caused by a drug or the inappropriate use of a drug. Retrospective record reviews in several countries have shown that anticoagulants frequently lead to hospital readmissions. In this study a hospital readmission is defined as an admission to the emergency department of the Jessa hospital. The objective of this study is to determine the incidence of one week and 30-day readmissions caused by (preventable) ADE's due to anticoagulants.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Hasselt, Belgium, 3500
        • Jessa Ziekenhuis
        • Contact:
        • Sub-Investigator:
          • kristel Marquet, drs.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients who received an anticoagulant on their last day of admission

Description

Inclusion Criteria:

  1. Patients who received an anticoagulant on their last day of admission
  2. Patients who were readmitted within 30 days
  3. Patients who were diagnosed using the pathology registration of the emergency department of the Jessa hospital

Exclusion Criteria:

  1. Patients who didn't receive an anticoagulant on their last day of admission
  2. Patients who were not readmitted within 30 days
  3. Patients who were not diagnosed using the pathology registration of the emergency department of the Jessa hospital
  4. Patients with missing data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
incidence of readmissions within one week caused by ADE's due to anticoagulants
Time Frame: up to one week
up to one week
incidence of readmissions within 30 days caused by ADE's due to anticoagulants
Time Frame: up to 1 month
up to 1 month
incidence of preventable ADE's leading to readmission
Time Frame: week 1, month 1
week 1, month 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Chair: Martijn Droogmans, pharmacist, Jessa hospital
  • Study Chair: Kristel Marquet, drs, Hasselt University
  • Study Chair: Janne Theuwissen, pharmacist, Jessa hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2014

Primary Completion (Anticipated)

September 1, 2014

Study Registration Dates

First Submitted

February 25, 2014

First Submitted That Met QC Criteria

February 25, 2014

First Posted (Estimate)

February 28, 2014

Study Record Updates

Last Update Posted (Estimate)

February 28, 2014

Last Update Submitted That Met QC Criteria

February 25, 2014

Last Verified

February 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • 14.05/APO14.01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Incidence of Readmissions

3
Subscribe